Hints and tips:
...Johnson & Johnson lost 0.6 per cent to $60.21 as the consumer products company said it would buy Micrus Endovascular for about $480m to expand its portfolio of medical devices that treat strokes....
...By lining up Abbott Laboratories as the buyer for Guidant’s vascular intervention and endovascular businesses, Boston should be able to speed up antitrust approvals....
...The deal with Abbott involves the sale of Guidant’s vascular intervention and endovascular businesses for $4.3bn in cash....
...Agreeing to sell Guidant’s vascular intervention and endovascular businesses, while largely offloading its drug eluting stent programme, is also likely to speed up competition approval....
...Boston said Abbott agreed to pay $4.1bn for Guidant’s vascular intervention and endovascular businesses, up from $3.8bn....
International Edition